preliminary findings in mcrpc for fractionated dose 177lu-psma-617
Published 5 years ago • 202 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
1:48
expert discusses fractionated dose 177lu-psma-617 in mcrpc
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
6:16
psma for prostate cancer -quick overview
-
25:26
psma theranostics for prostate cancer
-
11:01
lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
-
3:41
177lu-psma-617 vs. cabazitaxel for mcrpc
-
1:50
dr. gafita on sequencing 177lu-psma-617 in mcrpc
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
2:04
phase i/ii trial of 177lu−j591 and 177lu−psma−617 in mcrcp
-
1:38
177lu-psma i&t for patients with psma-positive mcrpc
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
-
0:28
177lu-psma-617 for metastatic castration-resistant prostate cancer
-
5:47
phase i/ii dose-escalation study of 225ac-j591 in progressive mcrpc
-
5:06
psmaddition: 177lu-psma-617 plus soc vs. soc alone in metastatic hormone-sensitive prostate cancer
-
0:56
analyzing responses to 177lupsma-617 in patients with metastatic crpc
-
14:39
just the beginning: what's next for radiotheranostics in prostate cancer?